Pub Date : 2025-11-14eCollection Date: 2025-01-01DOI: 10.47895/amp.vi0.10918
Leeland Anthony L Dela Luna, Ailyn M Yabes, Cecilia Nelia C Maramba-Lazarte, Irma R Makalinao, Lynn Crisanta R Panganiban, Richard Henry P Tiongco
Background and objective: The emergence of antimicrobial resistance (AMR) poses a significant global health threat, with developing countries such as the Philippines facing particularly severe impacts due to resource limitations. The most affected by AMR is Healthcare Acquired Infections (HAIs), including Catheter-Related Bloodstream Infections (CRBSIs). These are commonly associated with biofilm-forming bacteria like Staphylococcus epidermidis, which complicates treatment due to antibiotic resistance. The Philippine variety of Psidium guajava, a folklorically used medicinal plant, has shown potential antimicrobial properties that could offer a new avenue for combating resistant pathogens.
Methods: This study evaluated the antibacterial and antibiofilm efficacy of crude Psidium guajava ethanolic leaf extracts (PGELE) against biofilm-forming S. epidermidis (ATCC 12228). PGELE was tested at five concentrations (ranging from 312.5 µg/mL to 10,000 µg/mL) using two-fold serial dilution to determine the Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) using agar dilution count method. For the Minimum Biofilm Inhibitory Concentration (MBIC) and Minimum Biofilm Eradication Concentration (MBEC), crude PGELE was tested at 0.25 x MIC, 0.5 x MIC, MIC, 2 x MIC and 4 x MIC.
Results: The MIC for PGELE against S. epidermidis was determined to be 2500 µg/mL, and the MBC was 5000 µg/mL, indicating that PGELE exhibits bactericidal activity. In biofilm assays, PGELE demonstrated strong antibiofilm activity at concentrations as low as 625 µg/mL, inhibiting biofilm formation by more than 50%. However, PGELE did not eradicate preformed biofilms, as indicated by the MBEC results at concentrations ranging from 625 µg/mL to 10,000 µg/mL.
Conclusion: Psidium guajava ethanolic leaf extracts exhibit antibacterial and antibiofilm activities against S. epidermidis, particularly in preventing biofilm formation. These findings suggest that PGELE could be developed as an effective natural antimicrobial agent for use in healthcare settings to prevent CRBSIs and other infections caused by biofilm-forming pathogens. Further research and development are warranted to explore the potential of PGELE for antimicrobial drug development.
{"title":"Antibacterial and Biofilm-inhibiting Activity of the Crude <i>Psidium guajava</i> Ethanolic Leaf Extracts against Biofilm-forming <i>Staphylococcus epidermidis</i> (ATCC 12228).","authors":"Leeland Anthony L Dela Luna, Ailyn M Yabes, Cecilia Nelia C Maramba-Lazarte, Irma R Makalinao, Lynn Crisanta R Panganiban, Richard Henry P Tiongco","doi":"10.47895/amp.vi0.10918","DOIUrl":"10.47895/amp.vi0.10918","url":null,"abstract":"<p><strong>Background and objective: </strong>The emergence of antimicrobial resistance (AMR) poses a significant global health threat, with developing countries such as the Philippines facing particularly severe impacts due to resource limitations. The most affected by AMR is Healthcare Acquired Infections (HAIs), including Catheter-Related Bloodstream Infections (CRBSIs). These are commonly associated with biofilm-forming bacteria like <i>Staphylococcus epidermidis</i>, which complicates treatment due to antibiotic resistance. The Philippine variety of <i>Psidium guajava</i>, a folklorically used medicinal plant, has shown potential antimicrobial properties that could offer a new avenue for combating resistant pathogens.</p><p><strong>Methods: </strong>This study evaluated the antibacterial and antibiofilm efficacy of crude <i>Psidium guajava</i> ethanolic leaf extracts (PGELE) against biofilm-forming <i>S. epidermidis</i> (ATCC 12228). PGELE was tested at five concentrations (ranging from 312.5 µg/mL to 10,000 µg/mL) using two-fold serial dilution to determine the Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) using agar dilution count method. For the Minimum Biofilm Inhibitory Concentration (MBIC) and Minimum Biofilm Eradication Concentration (MBEC), crude PGELE was tested at 0.25 x MIC, 0.5 x MIC, MIC, 2 x MIC and 4 x MIC.</p><p><strong>Results: </strong>The MIC for PGELE against <i>S. epidermidis</i> was determined to be 2500 µg/mL, and the MBC was 5000 µg/mL, indicating that PGELE exhibits bactericidal activity. In biofilm assays, PGELE demonstrated strong antibiofilm activity at concentrations as low as 625 µg/mL, inhibiting biofilm formation by more than 50%. However, PGELE did not eradicate preformed biofilms, as indicated by the MBEC results at concentrations ranging from 625 µg/mL to 10,000 µg/mL.</p><p><strong>Conclusion: </strong><i>Psidium guajava</i> ethanolic leaf extracts exhibit antibacterial and antibiofilm activities against <i>S. epidermidis</i>, particularly in preventing biofilm formation. These findings suggest that PGELE could be developed as an effective natural antimicrobial agent for use in healthcare settings to prevent CRBSIs and other infections caused by biofilm-forming pathogens. Further research and development are warranted to explore the potential of PGELE for antimicrobial drug development.</p>","PeriodicalId":6994,"journal":{"name":"Acta Medica Philippina","volume":"59 17","pages":"86-97"},"PeriodicalIF":0.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12697216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-14eCollection Date: 2025-01-01DOI: 10.47895/amp.vi0.10438
Madeleine de Rosas-Valera, Julienne Clarize P Lechuga, Lourdes Risa S Yapchiongco, Necy S Juat, Mary Juliet De Rosas-Labitigan, Maria Lourdes E Amarillo, Leo M Flores, Maebel Audrey R Joaquin, Adelberto R Lambinicio
<p><strong>Objectives: </strong>The aim of the study is to estimate the cost of breast cancer diagnosis, treatment, and management in the Philippines. Specifically, it aims to identify the resource requirements and interventions related to breast cancer diagnosis, treatment, and management, measure resource volumes (number of units), learn to value resource items (unit costs), and determine the total cost of treatment per disease stage.</p><p><strong>Methods: </strong>The study covered nine tertiary hospitals, seven of which were government hospitals and two were private hospitals, with all tertiary hospitals providing breast cancer services and accredited by Philippine Health Insurance Corporation (PHIC or PhilHealth) for the Z-Benefit Package. Interventions and services related to breast cancer included radiographic procedures, laboratory and imaging tests, chemotherapy drugs and medications, medical and surgical supplies, surgical rates (for breast surgery), accommodation, staff time and salary/professional fees, and other procedure fees. The study conducted in 2022, examined cost prices of breast cancer interventions and services from stage 1-3B.Purposive and convenience sampling were used based on PhilHealth accreditation and willingness of hospitals to participate in the study. The study conducted a focus group discussion with oncologists, radiologists, anesthesiologists, and other health care providers to validate the clinical guideline used and to solicit inputs to the costing design, analysis framework, and tools for data collection. Data collection of financial cost information (charge price) was conducted using a set of costing matrices filled out by the various departments of the hospitals. Costs and median rates were calculated across hospitals on diagnostics and imaging tests, surgery costs of both public and private facilities, medical treatment, and radiotherapy.</p><p><strong>Results: </strong>Breast MRI, Breast Panel, and Chest CT Scan are the top 3 most expensive diagnostic procedures ranging from PhP 8,102.00 to PhP 9,800.00 per procedure. Surgical procedures for breast cancer at private hospitals and public hospitals showed huge differences in costs. The cost of a cycle of chemotherapy ranges from PhP 596.70 to PhP 3,700.00 per session, while the cost of targeted therapy can cost up to PhP 46,394.21 per session. A year of hormone therapy ranges from PhP 3,276.00 with the use of Tamoxifen, and up to PhP 68,284.00 with Goserelin. Aromatase inhibitors such as Anastrozole and Letrozole cost from PhP 18,000 to PhP 36,000, respectively. Multiple cycles depending on the diagnosis are prescribed per patient and used in combination with other chemotherapy medications or other therapies such as targeted therapy and hormone therapy are usually taken daily up to 5 to 10 years. Conventional radiotherapy can cost up to PhP 88,150.00 covering 28 sessions, CT simulation, and CT planning.</p><p><strong>Conclusion: </strong>This cost study pro
目的:本研究的目的是估计菲律宾乳腺癌诊断、治疗和管理的成本。具体而言,它旨在确定与乳腺癌诊断、治疗和管理相关的资源需求和干预措施,测量资源量(单位数量),学习评估资源项目(单位成本),并确定每个疾病阶段的治疗总成本。方法:研究对象为9家三级医院,其中7家为政府医院,2家为私立医院,所有三级医院均提供乳腺癌服务,并经菲律宾健康保险公司(Philippine Health Corporation,简称:Philippine Health)认证为Z-Benefit Package。与乳腺癌有关的干预措施和服务包括放射检查程序、实验室和成像检查、化疗药物和药物、医疗和手术用品、手术费率(乳房手术)、住宿、工作人员时间和工资/专业费用以及其他程序费用。该研究于2022年进行,调查了1-3B期乳腺癌干预和服务的成本价格。基于PhilHealth认证和医院参与研究的意愿,采用了目的性和便利性抽样。该研究与肿瘤科医生、放射科医生、麻醉科医生和其他医疗保健提供者进行了焦点小组讨论,以验证所使用的临床指南,并征求对成本计算设计、分析框架和数据收集工具的输入。财务成本信息(收费价格)的数据收集使用由医院各部门填写的一套成本计算矩阵进行。计算了各医院的诊断和影像学检查、公立和私立医院的手术费用、医疗和放射治疗费用和中位数费用。结果:乳房MRI,乳房面板和胸部CT扫描是最昂贵的3种诊断程序,每项程序从8,102.00比索到9,800.00比索不等。私立医院和公立医院的乳腺癌手术费用差异很大。化疗周期的费用从每次596.70至3,700菲律宾比索不等,而靶向治疗的费用可高达每次46,394.21菲律宾比索。一年的激素治疗费用从使用他莫昔芬的3276.00比索到使用戈舍林的68284.00比索不等。芳香酶抑制剂如阿那曲唑和来曲唑的价格分别为1.8万至3.6万菲律宾比索。根据诊断为每个病人开出多个周期,并与其他化疗药物或其他疗法(如靶向治疗和激素治疗)联合使用,通常每天服用5至10年。常规放射治疗包括28个疗程、CT模拟和CT规划,费用高达88,150菲律宾比索。结论:本成本研究提供了相关信息和更好的视角,有利于发展的福利,为卫生部门的政策制定在哪里和如何重点支持病人的财务准备,以应对医疗和金融灾难。PhilHealth需要指导医疗保健提供者使用他们的成本计算方法,并开发他们自己的集成的、可互操作的和全面的成本数据库。委员会建议政府拨出预算,为早期诊断病人的筛查和评估提供资金,并降低癌症治疗的卫生支出费用。
{"title":"Breast Cancer in the Philippines: A Financing Cost Assessment Study.","authors":"Madeleine de Rosas-Valera, Julienne Clarize P Lechuga, Lourdes Risa S Yapchiongco, Necy S Juat, Mary Juliet De Rosas-Labitigan, Maria Lourdes E Amarillo, Leo M Flores, Maebel Audrey R Joaquin, Adelberto R Lambinicio","doi":"10.47895/amp.vi0.10438","DOIUrl":"10.47895/amp.vi0.10438","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of the study is to estimate the cost of breast cancer diagnosis, treatment, and management in the Philippines. Specifically, it aims to identify the resource requirements and interventions related to breast cancer diagnosis, treatment, and management, measure resource volumes (number of units), learn to value resource items (unit costs), and determine the total cost of treatment per disease stage.</p><p><strong>Methods: </strong>The study covered nine tertiary hospitals, seven of which were government hospitals and two were private hospitals, with all tertiary hospitals providing breast cancer services and accredited by Philippine Health Insurance Corporation (PHIC or PhilHealth) for the Z-Benefit Package. Interventions and services related to breast cancer included radiographic procedures, laboratory and imaging tests, chemotherapy drugs and medications, medical and surgical supplies, surgical rates (for breast surgery), accommodation, staff time and salary/professional fees, and other procedure fees. The study conducted in 2022, examined cost prices of breast cancer interventions and services from stage 1-3B.Purposive and convenience sampling were used based on PhilHealth accreditation and willingness of hospitals to participate in the study. The study conducted a focus group discussion with oncologists, radiologists, anesthesiologists, and other health care providers to validate the clinical guideline used and to solicit inputs to the costing design, analysis framework, and tools for data collection. Data collection of financial cost information (charge price) was conducted using a set of costing matrices filled out by the various departments of the hospitals. Costs and median rates were calculated across hospitals on diagnostics and imaging tests, surgery costs of both public and private facilities, medical treatment, and radiotherapy.</p><p><strong>Results: </strong>Breast MRI, Breast Panel, and Chest CT Scan are the top 3 most expensive diagnostic procedures ranging from PhP 8,102.00 to PhP 9,800.00 per procedure. Surgical procedures for breast cancer at private hospitals and public hospitals showed huge differences in costs. The cost of a cycle of chemotherapy ranges from PhP 596.70 to PhP 3,700.00 per session, while the cost of targeted therapy can cost up to PhP 46,394.21 per session. A year of hormone therapy ranges from PhP 3,276.00 with the use of Tamoxifen, and up to PhP 68,284.00 with Goserelin. Aromatase inhibitors such as Anastrozole and Letrozole cost from PhP 18,000 to PhP 36,000, respectively. Multiple cycles depending on the diagnosis are prescribed per patient and used in combination with other chemotherapy medications or other therapies such as targeted therapy and hormone therapy are usually taken daily up to 5 to 10 years. Conventional radiotherapy can cost up to PhP 88,150.00 covering 28 sessions, CT simulation, and CT planning.</p><p><strong>Conclusion: </strong>This cost study pro","PeriodicalId":6994,"journal":{"name":"Acta Medica Philippina","volume":"59 17","pages":"7-15"},"PeriodicalIF":0.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12697210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-14eCollection Date: 2025-01-01DOI: 10.47895/amp.vi0.10939
Mario B Prado, Manuel Peter Paul C Jorge
Background: While wearing face shields and other gears to protect the facial mucous membranes not covered by face masks are proven to decrease the odds of infection in the hospital setting, there is no concrete evidence of its efficacy in the general public.
Objective: To determine the effectiveness of face shield use in the general public in the local setting.
Methods: This study utilized an ecological study design, with the weeks when the policy was implemented serving as the exposure variable while the weeks when the policy was not in effect, whether prior to or after, serving as control. Primary outcomes were mean incidence of COVID-19 and case fatality rate (CFR) per week.
Results: When the mandatory face shield use was implemented, the mean incidence of COVID-19 per week was higher compared to weeks when it was not implemented [93 cases per 1000 population per week (ptpw) vs 65 cases, relative risk:1.43, z=-3.79, p=0.0001]. Moreover, during weeks when only less than 50% of the population was vaccinated with first dose (93 cases ptpw vs 52 cases, RR: 1.79, z=-4.3, p<0.0001) and complete doses (93 cases ptpw vs 66 cases ptpw, RR:1.41, z=-3.69, p=0.0002), the mean incidence of COVID-19 per week were statistically higher in weeks when face shield use was in effect. Controlling the status of vaccination and the predominant strain, face shield use increased the incidence of COVID-19 cases ptpw by 38 (F=13, R2=39%, p=0.026) to 50 (F=3.06, R2=12.2%, p=0.032) compared to no face shield use. No difference in CFR between weeks with face shield use and no face shield use was seen (29 deaths ptpw vs 32 deaths per ptpw, p=1.0). Nevertheless, when the weeks with no vaccination (27 deaths ptpw vs 48 deaths ptpw, RR=0.56, p=0.0018), less than 50% of the population were vaccinated with first dose (30 deaths ptpw vs 50 deaths ptpw, RR:0.6, p=0.0005), and complete doses (30 deaths vs 47 deaths ptpw, RR:0.64, p=0.0042) were only considered, face shield use significantly decreased the mean CFR per week. Controlling the incidence rate of COVID-19, vaccination status, and prevalent strain, face shield use decreases the number of deaths by 26 per 1000 COVID-19 diagnosed cases (F=7.4, R2=28.3, p=0.010).
Conclusions: In general, although face shield use increased susceptibility to COVID-19, it decreased case fatality rate in the Philippines. However, a more robust and controlled study in the future may be needed to truly justify its recommendation for the public.
背景:虽然戴面罩和其他装备来保护未被口罩覆盖的面部粘膜已被证明可以降低医院环境中的感染几率,但没有具体证据表明其对公众有效。目的:了解当地普通民众使用面罩的有效性。方法:本研究采用生态学研究设计,将政策实施的周数作为暴露变量,而政策实施之前或之后未实施的周数作为对照。主要结局为每周平均COVID-19发病率和病死率(CFR)。结果:强制使用面罩时,每周COVID-19的平均发病率高于未实施的周[每1000人每周93例(ptpw) vs 65例,相对风险:1.43,z=-3.79, p=0.0001]。此外,与不使用面罩相比,只有不到50%的人口接种了第一剂疫苗(93例ptpw vs 52例,RR: 1.79, z=-4.3, p2=39%, p=0.026)至50例(F=3.06, R2=12.2%, p=0.032)。使用面罩和不使用面罩的周间CFR无差异(每ptpw有29例死亡vs 32例死亡,p=1.0)。然而,当未接种疫苗的周数(27例死亡ptpw vs 48例死亡ptpw, RR=0.56, p=0.0018),仅考虑不到50%的人口接种了第一剂疫苗(30例死亡ptpw vs 50例死亡ptpw, RR:0.6, p=0.0005)和完整剂量(30例死亡对47例死亡ptpw, RR:0.64, p=0.0042)时,面罩的使用显著降低了每周的平均CFR。在控制COVID-19发病率、疫苗接种状况和流行毒株的情况下,使用面罩可使每1000例COVID-19诊断病例的死亡人数减少26人(F=7.4, R2=28.3, p=0.010)。结论:总体而言,尽管使用面罩增加了对COVID-19的易感性,但它降低了菲律宾的病死率。然而,未来可能需要一项更有力和可控的研究来真正证明其对公众的建议是合理的。
{"title":"Impact on Transmissibility and Case Fatality Rate of COVID-19 of the Mandatory Face Shield Use in Addition to Mask during the Pandemic: The Philippine Experience.","authors":"Mario B Prado, Manuel Peter Paul C Jorge","doi":"10.47895/amp.vi0.10939","DOIUrl":"10.47895/amp.vi0.10939","url":null,"abstract":"<p><strong>Background: </strong>While wearing face shields and other gears to protect the facial mucous membranes not covered by face masks are proven to decrease the odds of infection in the hospital setting, there is no concrete evidence of its efficacy in the general public.</p><p><strong>Objective: </strong>To determine the effectiveness of face shield use in the general public in the local setting.</p><p><strong>Methods: </strong>This study utilized an ecological study design, with the weeks when the policy was implemented serving as the exposure variable while the weeks when the policy was not in effect, whether prior to or after, serving as control. Primary outcomes were mean incidence of COVID-19 and case fatality rate (CFR) per week.</p><p><strong>Results: </strong>When the mandatory face shield use was implemented, the mean incidence of COVID-19 per week was higher compared to weeks when it was not implemented [93 cases per 1000 population per week (ptpw) vs 65 cases, relative risk:1.43, z=-3.79, p=0.0001]. Moreover, during weeks when only less than 50% of the population was vaccinated with first dose (93 cases ptpw vs 52 cases, RR: 1.79, z=-4.3, p<0.0001) and complete doses (93 cases ptpw vs 66 cases ptpw, RR:1.41, z=-3.69, p=0.0002), the mean incidence of COVID-19 per week were statistically higher in weeks when face shield use was in effect. Controlling the status of vaccination and the predominant strain, face shield use increased the incidence of COVID-19 cases ptpw by 38 (F=13, R<sup>2</sup>=39%, p=0.026) to 50 (F=3.06, R<sup>2</sup>=12.2%, p=0.032) compared to no face shield use. No difference in CFR between weeks with face shield use and no face shield use was seen (29 deaths ptpw vs 32 deaths per ptpw, p=1.0). Nevertheless, when the weeks with no vaccination (27 deaths ptpw vs 48 deaths ptpw, RR=0.56, p=0.0018), less than 50% of the population were vaccinated with first dose (30 deaths ptpw vs 50 deaths ptpw, RR:0.6, p=0.0005), and complete doses (30 deaths vs 47 deaths ptpw, RR:0.64, p=0.0042) were only considered, face shield use significantly decreased the mean CFR per week. Controlling the incidence rate of COVID-19, vaccination status, and prevalent strain, face shield use decreases the number of deaths by 26 per 1000 COVID-19 diagnosed cases (F=7.4, R<sup>2</sup>=28.3, p=0.010).</p><p><strong>Conclusions: </strong>In general, although face shield use increased susceptibility to COVID-19, it decreased case fatality rate in the Philippines. However, a more robust and controlled study in the future may be needed to truly justify its recommendation for the public.</p>","PeriodicalId":6994,"journal":{"name":"Acta Medica Philippina","volume":"59 17","pages":"98-104"},"PeriodicalIF":0.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12697215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-14eCollection Date: 2025-01-01DOI: 10.47895/amp.vi0.11335
Mark Gideon M Wallis, Jannette D Awisan
Background and objectives: Municipal solid waste workers (MSWWs) are important in the city's waste management. With these vital contributions, they face unique occupational hazards and health risks. This study aims to determine the prevalence of occupational infections, such as soil-transmitted helminth infections (STHI) and hepatitis A virus (HAV), as well as the occurrence of Helicobacter pylori infection among the MSWWs of Baguio City.
Methods: This cross-sectional analytic study collected data from volunteer MSWWs using a questionnaire to gather information on age, duration of employment, use of gloves in the workplace, and hand hygiene practices. Stool samples were obtained from participants and were analyzed for STHI using the Formalin Ether Concentration Technique (FECT). H. pylori infection was detected using the SD Bioline rapid antigen test kit on stool samples while blood samples were collected and tested for HAV antibodies using the Aria IgG/IgM rapid test kit.
Results: Of the 44 volunteer MSWWs tested, 25 were infected with hazardous pathogens. Specifically, six workers (13.6%) were infected with STHI, four (9.1%) were infected with HAV and 15 (34.1%) were infected with H. pylori. Among those infected with STHI, Ascaris lumbricoides and Endolimax nana were the predominant species, each with a prevalence rate of 33.3%. In contrast, Blastocystis hominis and hookworm infections each had a prevalence rate of 16.7%. A significant association was found between STHI prevalence and the preference for alcohol hand rubs over hand washing, with a p-value of 0.008.
Conclusion: The analysis revealed a significant association between the prevalence of STHI and the preference for alcohol hand rubs over hand washing, suggesting that MSWWs may have a false sense of security regarding their hygiene practices. The findings revealed the critical importance of proper hand washing in preventing STHI. Future research should expand data collection to encompass a broader range of socio-demographic, environmental, and lifestyle factors that may influence infection rates. Additionally, including a control group of individuals not exposed to waste management could help differentiate between factors specific to waste handling and those related to other occupations. This study emphasizes the need for collaborative efforts among researchers, public health authorities, and waste management agencies to enhance the health and safety of MSWWs while addressing broader public health concerns related to waste management practices.
{"title":"Prevalence of Soil-transmitted Helminth, Hepatitis A, and <i>Helicobacter pylori</i> Infections among Municipal Solid Waste Workers in Baguio City.","authors":"Mark Gideon M Wallis, Jannette D Awisan","doi":"10.47895/amp.vi0.11335","DOIUrl":"10.47895/amp.vi0.11335","url":null,"abstract":"<p><strong>Background and objectives: </strong>Municipal solid waste workers (MSWWs) are important in the city's waste management. With these vital contributions, they face unique occupational hazards and health risks. This study aims to determine the prevalence of occupational infections, such as soil-transmitted helminth infections (STHI) and hepatitis A virus (HAV), as well as the occurrence of <i>Helicobacter pylori</i> infection among the MSWWs of Baguio City.</p><p><strong>Methods: </strong>This cross-sectional analytic study collected data from volunteer MSWWs using a questionnaire to gather information on age, duration of employment, use of gloves in the workplace, and hand hygiene practices. Stool samples were obtained from participants and were analyzed for STHI using the Formalin Ether Concentration Technique (FECT). <i>H. pylori</i> infection was detected using the SD Bioline rapid antigen test kit on stool samples while blood samples were collected and tested for HAV antibodies using the Aria IgG/IgM rapid test kit.</p><p><strong>Results: </strong>Of the 44 volunteer MSWWs tested, 25 were infected with hazardous pathogens. Specifically, six workers (13.6%) were infected with STHI, four (9.1%) were infected with HAV and 15 (34.1%) were infected with <i>H. pylori</i>. Among those infected with STHI, <i>Ascaris lumbricoides</i> and <i>Endolimax nana</i> were the predominant species, each with a prevalence rate of 33.3%. In contrast, <i>Blastocystis hominis</i> and hookworm infections each had a prevalence rate of 16.7%. A significant association was found between STHI prevalence and the preference for alcohol hand rubs over hand washing, with a p-value of 0.008.</p><p><strong>Conclusion: </strong>The analysis revealed a significant association between the prevalence of STHI and the preference for alcohol hand rubs over hand washing, suggesting that MSWWs may have a false sense of security regarding their hygiene practices. The findings revealed the critical importance of proper hand washing in preventing STHI. Future research should expand data collection to encompass a broader range of socio-demographic, environmental, and lifestyle factors that may influence infection rates. Additionally, including a control group of individuals not exposed to waste management could help differentiate between factors specific to waste handling and those related to other occupations. This study emphasizes the need for collaborative efforts among researchers, public health authorities, and waste management agencies to enhance the health and safety of MSWWs while addressing broader public health concerns related to waste management practices.</p>","PeriodicalId":6994,"journal":{"name":"Acta Medica Philippina","volume":"59 17","pages":"24-31"},"PeriodicalIF":0.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12697214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-14eCollection Date: 2025-01-01DOI: 10.47895/amp.vi0.10792
Cheryll Magbanua-Calalo, Ebner Bon G Maceda, Maria Melanie Liberty B Alcausin
Background: Osteogenesis imperfecta (OI) is a group of connective tissue disease characterized by propensity to fractures following minimal trauma. OI is a lifelong inheritable disease and currently has no definitive cure. Management goals are directed towards prevention of fractures, controlling the symptoms, maximizing independent mobility, and developing optimal bone mass and muscle strength. Bisphosphonates are the mainstay of pharmacologic fracture-prevention therapy for most forms of OI. The University of the Philippines-Philippine General Hospital Bisphosphonate Treatment Program for OI was started in 2006 by the Clinical Genetics Service. For more than a decade now, the program has been serving more than 50 OI patients. This study evaluated the clinical outcomes of the patients who were included in the program to add to the body of knowledge on Filipino patients with OI.
Objectives: This study sought to determine the clinical outcomes of children with OI on intravenous pamidronate treatment at the Philippine General Hospital (PGH) from January 2010 to December 2018.
Methods: The study utilized a retrospective review of medical records of 24 patients diagnosed with OI on pamidronate therapy seen at the PGH from January 2010 to December 2018. Descriptive statistics were used to summarize the demographic and baseline clinical characteristics of the patients. Median annualized fracture rates before and during treatment were calculated and compared. The patient functional mobility before and during pamidronate infusion was classified accordingly based on the Gross Motor Function Classification System (GMFCS) and were compared.
Results: Twenty-four patients, which include seven males and 17 females, with ages at the time of conduct of the study ranging from four years to 11 years, fulfilled the inclusion criteria. There were four patients with OI type I, six with OI type III, 11 with OI type IV and three with OI type V. The annualized long bone fracture rate decreased significantly from a median of 2.0/year (range 1-2.75) to 0.75/year (range 0-1) after more than a year on pamidronate infusion (p<0.001). There is a note of overall improvement in terms of functional mobility using the 5-point scale of the GMFCS during pamidronate infusion from the baseline. However, the difference is not statistically significant.
Conclusion: Cyclic intravenous pamidronate treatment in young children with moderate-severe OI is well tolerated and associated with reduced fracture frequency with a tendency to improvement of gross functional mobility.
{"title":"Clinical Outcome of Patients with Osteogenesis Imperfecta on Intravenous Pamidronate Treatment at the Philippine General Hospital from 2010-2018.","authors":"Cheryll Magbanua-Calalo, Ebner Bon G Maceda, Maria Melanie Liberty B Alcausin","doi":"10.47895/amp.vi0.10792","DOIUrl":"10.47895/amp.vi0.10792","url":null,"abstract":"<p><strong>Background: </strong>Osteogenesis imperfecta (OI) is a group of connective tissue disease characterized by propensity to fractures following minimal trauma. OI is a lifelong inheritable disease and currently has no definitive cure. Management goals are directed towards prevention of fractures, controlling the symptoms, maximizing independent mobility, and developing optimal bone mass and muscle strength. Bisphosphonates are the mainstay of pharmacologic fracture-prevention therapy for most forms of OI. The University of the Philippines-Philippine General Hospital Bisphosphonate Treatment Program for OI was started in 2006 by the Clinical Genetics Service. For more than a decade now, the program has been serving more than 50 OI patients. This study evaluated the clinical outcomes of the patients who were included in the program to add to the body of knowledge on Filipino patients with OI.</p><p><strong>Objectives: </strong>This study sought to determine the clinical outcomes of children with OI on intravenous pamidronate treatment at the Philippine General Hospital (PGH) from January 2010 to December 2018.</p><p><strong>Methods: </strong>The study utilized a retrospective review of medical records of 24 patients diagnosed with OI on pamidronate therapy seen at the PGH from January 2010 to December 2018. Descriptive statistics were used to summarize the demographic and baseline clinical characteristics of the patients. Median annualized fracture rates before and during treatment were calculated and compared. The patient functional mobility before and during pamidronate infusion was classified accordingly based on the Gross Motor Function Classification System (GMFCS) and were compared.</p><p><strong>Results: </strong>Twenty-four patients, which include seven males and 17 females, with ages at the time of conduct of the study ranging from four years to 11 years, fulfilled the inclusion criteria. There were four patients with OI type I, six with OI type III, 11 with OI type IV and three with OI type V. The annualized long bone fracture rate decreased significantly from a median of 2.0/year (range 1-2.75) to 0.75/year (range 0-1) after more than a year on pamidronate infusion (p<0.001). There is a note of overall improvement in terms of functional mobility using the 5-point scale of the GMFCS during pamidronate infusion from the baseline. However, the difference is not statistically significant.</p><p><strong>Conclusion: </strong>Cyclic intravenous pamidronate treatment in young children with moderate-severe OI is well tolerated and associated with reduced fracture frequency with a tendency to improvement of gross functional mobility.</p>","PeriodicalId":6994,"journal":{"name":"Acta Medica Philippina","volume":"59 17","pages":"69-75"},"PeriodicalIF":0.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12697208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-14eCollection Date: 2025-01-01DOI: 10.47895/amp.vi0.10852
Kelechi Precious Ogbonnaya, Leonila A Estole-Casanova, Cecilia A Jimeno, Lynn Crisanta R Panganiban, Maria Stella T Giron, Richard Henry P Tiongco
<p><strong>Background and objective: </strong>Diabetes, a prevalent metabolic disorder characterized by hyperglycemia primarily due to insulin action and secretion, poses significant health challenges, particularly in low to medium-income countries such as the Philippines. <i>Quassia amara,</i> a shrub indigenous to South America and present in the Philippines, holds a rich history of utilization in alternative and complementary therapies. While previous studies have demonstrated the hypoglycemic effects of <i>Quassia amara</i> stem wood, investigations into the potential impact of its leaves on blood glucose levels remain scarce. Thus, this study aimed to assess the blood glucose-lowering effects of the aqueous leaf extract of <i>Quassia amara</i> (ALQa) on ICR strain mice.</p><p><strong>Methods: </strong>Diabetes was induced in thirty male ICR mice via intraperitoneal administration of alloxan mono-hydrate (200 mg/kg) dissolved in 0.9% Normal Saline. The mice were divided into five groups (n=6), Group I: negative control (distilled water), Group II: reference standard glibenclamide (4 mg/kg): Groups III-V: three doses of ALQa (125, 250, and 500 mg/kg) via oral gavage. A glucometer was used to monitor the fasting blood glucose levels at 0, 1-, 2-, 6-, and 24-hour post-administration.</p><p><strong>Results: </strong>Administration of alloxan monohydrate increased the FBS in the treated group to diabetic levels of >200 mg/dL. The treatment of diabetic mice with ALQa extract significantly reduced fasting blood sugar (FBS) levels in a dose-dependent manner with the highest dose of ALQa (500 mg/kg) having glucose-lowering effects comparable to glibenclamide beginning with the 2-hour mark until 24-hour post-intervention. The mean FBS at 0-hour (baseline) and 1-hour post-intervention were similar for all the groups. However, there was an increase in the mean FBS of the negative control group treated with distilled water in the first hour while there was already a decrease in the FBS of those allocated to glibenclamide and the three doses of ALQa. At both the second and 6-hour mark post-intervention, the mean FBS of the mice treated with ALQa 250 mg/kg and 500 mg/kg was comparable to glibenclamide. Finally, at the 24<sup>th</sup> hour post-intervention, only the mice allocated to 500 mg/kg of ALQa had comparable FBS to glibenclamide. The degree of reduction [mean percent reduction] of the FBS from baseline to the 24<sup>th</sup> hour was 78% for glibenclamide and 69% for ALQa 500 mg/kg (p =0.816).</p><p><strong>Conclusions: </strong>The aqueous extract of <i>Quassia amara</i> leaf at 250 and 500 mg/kg produced a dose-dependent significant blood glucose-lowering effect in the alloxan-induced diabetic mice model. The 500 mg dose demonstrated a statistically comparable reduction in FBS to glibenclamide from the 2-hour time point. These findings suggest the potential of ALQa as an antidiabetic agent. Thus, warranting further investigation into its therapeut
{"title":"Evaluation of the Blood Glucose-Lowering Effect of the Aqueous Leaf Extract of <i>Quassia amara</i> L. (Simaroubaceae) on Alloxan-induced Diabetes in Male ICR Mice (<i>Mus musculus</i>).","authors":"Kelechi Precious Ogbonnaya, Leonila A Estole-Casanova, Cecilia A Jimeno, Lynn Crisanta R Panganiban, Maria Stella T Giron, Richard Henry P Tiongco","doi":"10.47895/amp.vi0.10852","DOIUrl":"10.47895/amp.vi0.10852","url":null,"abstract":"<p><strong>Background and objective: </strong>Diabetes, a prevalent metabolic disorder characterized by hyperglycemia primarily due to insulin action and secretion, poses significant health challenges, particularly in low to medium-income countries such as the Philippines. <i>Quassia amara,</i> a shrub indigenous to South America and present in the Philippines, holds a rich history of utilization in alternative and complementary therapies. While previous studies have demonstrated the hypoglycemic effects of <i>Quassia amara</i> stem wood, investigations into the potential impact of its leaves on blood glucose levels remain scarce. Thus, this study aimed to assess the blood glucose-lowering effects of the aqueous leaf extract of <i>Quassia amara</i> (ALQa) on ICR strain mice.</p><p><strong>Methods: </strong>Diabetes was induced in thirty male ICR mice via intraperitoneal administration of alloxan mono-hydrate (200 mg/kg) dissolved in 0.9% Normal Saline. The mice were divided into five groups (n=6), Group I: negative control (distilled water), Group II: reference standard glibenclamide (4 mg/kg): Groups III-V: three doses of ALQa (125, 250, and 500 mg/kg) via oral gavage. A glucometer was used to monitor the fasting blood glucose levels at 0, 1-, 2-, 6-, and 24-hour post-administration.</p><p><strong>Results: </strong>Administration of alloxan monohydrate increased the FBS in the treated group to diabetic levels of >200 mg/dL. The treatment of diabetic mice with ALQa extract significantly reduced fasting blood sugar (FBS) levels in a dose-dependent manner with the highest dose of ALQa (500 mg/kg) having glucose-lowering effects comparable to glibenclamide beginning with the 2-hour mark until 24-hour post-intervention. The mean FBS at 0-hour (baseline) and 1-hour post-intervention were similar for all the groups. However, there was an increase in the mean FBS of the negative control group treated with distilled water in the first hour while there was already a decrease in the FBS of those allocated to glibenclamide and the three doses of ALQa. At both the second and 6-hour mark post-intervention, the mean FBS of the mice treated with ALQa 250 mg/kg and 500 mg/kg was comparable to glibenclamide. Finally, at the 24<sup>th</sup> hour post-intervention, only the mice allocated to 500 mg/kg of ALQa had comparable FBS to glibenclamide. The degree of reduction [mean percent reduction] of the FBS from baseline to the 24<sup>th</sup> hour was 78% for glibenclamide and 69% for ALQa 500 mg/kg (p =0.816).</p><p><strong>Conclusions: </strong>The aqueous extract of <i>Quassia amara</i> leaf at 250 and 500 mg/kg produced a dose-dependent significant blood glucose-lowering effect in the alloxan-induced diabetic mice model. The 500 mg dose demonstrated a statistically comparable reduction in FBS to glibenclamide from the 2-hour time point. These findings suggest the potential of ALQa as an antidiabetic agent. Thus, warranting further investigation into its therapeut","PeriodicalId":6994,"journal":{"name":"Acta Medica Philippina","volume":"59 17","pages":"39-49"},"PeriodicalIF":0.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12697213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-14eCollection Date: 2025-01-01DOI: 10.47895/amp.v59i17.13853
Beatrice J Tiangco
{"title":"The All-of-Society Approach to Evidence-informed Policymaking in the Implementation of the Universal Healthcare Act of 2019.","authors":"Beatrice J Tiangco","doi":"10.47895/amp.v59i17.13853","DOIUrl":"https://doi.org/10.47895/amp.v59i17.13853","url":null,"abstract":"","PeriodicalId":6994,"journal":{"name":"Acta Medica Philippina","volume":"59 17","pages":"5-6"},"PeriodicalIF":0.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12697211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-14eCollection Date: 2025-01-01DOI: 10.47895/amp.vi0.10465
Raissa Marie M Tud, Analyn T Fuentes-Fallarme
Background and objective: Tuberculosis (TB) remains to be prevalent in the Philippines and globally. Female genital tuberculosis has devastating and permanent consequences, hence, timely and adequate treatment is needed. Since more data regarding optimal duration of treatment of genital tuberculosis are needed, this study compares the treatment response at six months and after at least nine months of treatment, with the intention of determining the most practical management for genital tuberculosis.
Methods: A retrospective chart review was conducted for newly diagnosed cases of genital tuberculosis who met the inclusion criteria. Treatment response was categorized into clinical, microbiologic, histologic, radiologic, and sonographic responses. Responses to treatment were evaluated as either partial or complete at the 6th month and after at least 9 months of treatment, and the proportions were compared.
Results: Out of 140 charts retrieved, only 43 were included. Statistically significant difference was found only in clinical response, primarily due to patients who did not achieve resumption of menstruation within the first six months of treatment. The rest of the treatment responses and adverse drug events are equally the same for both time periods.
Conclusion: Results of this study show that the proportion of patients with microbiologic, histologic, radiologic, and sonographic response to treatment at the 6th month did not significantly differ to the proportion of patients who responded at the 9th or 12th month of treatment. This leads to a conclusion that the 6-month treatment regimen will be more practical in treating genital tuberculosis, except in amenorrheic premenopausal women who may warrant extension of treatment. Further studies on post-treatment rates of relapse and sonographic resolution are needed.
{"title":"A Retrospective Comparison of Treatment Response between Short Course (6 months) and Extended Course (9 to 12 months) among Filipino Women with Genital Tract Tuberculosis who underwent Medical Management in a Tertiary Government Hospital from January 2015 to March 2020.","authors":"Raissa Marie M Tud, Analyn T Fuentes-Fallarme","doi":"10.47895/amp.vi0.10465","DOIUrl":"10.47895/amp.vi0.10465","url":null,"abstract":"<p><strong>Background and objective: </strong>Tuberculosis (TB) remains to be prevalent in the Philippines and globally. Female genital tuberculosis has devastating and permanent consequences, hence, timely and adequate treatment is needed. Since more data regarding optimal duration of treatment of genital tuberculosis are needed, this study compares the treatment response at six months and after at least nine months of treatment, with the intention of determining the most practical management for genital tuberculosis.</p><p><strong>Methods: </strong>A retrospective chart review was conducted for newly diagnosed cases of genital tuberculosis who met the inclusion criteria. Treatment response was categorized into clinical, microbiologic, histologic, radiologic, and sonographic responses. Responses to treatment were evaluated as either partial or complete at the 6<sup>th</sup> month and after at least 9 months of treatment, and the proportions were compared.</p><p><strong>Results: </strong>Out of 140 charts retrieved, only 43 were included. Statistically significant difference was found only in clinical response, primarily due to patients who did not achieve resumption of menstruation within the first six months of treatment. The rest of the treatment responses and adverse drug events are equally the same for both time periods.</p><p><strong>Conclusion: </strong>Results of this study show that the proportion of patients with microbiologic, histologic, radiologic, and sonographic response to treatment at the 6<sup>th</sup> month did not significantly differ to the proportion of patients who responded at the 9<sup>th</sup> or 12<sup>th</sup> month of treatment. This leads to a conclusion that the 6-month treatment regimen will be more practical in treating genital tuberculosis, except in amenorrheic premenopausal women who may warrant extension of treatment. Further studies on post-treatment rates of relapse and sonographic resolution are needed.</p>","PeriodicalId":6994,"journal":{"name":"Acta Medica Philippina","volume":"59 17","pages":"50-56"},"PeriodicalIF":0.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12697207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-14eCollection Date: 2025-01-01DOI: 10.47895/amp.vi0.11965
Lorna R Abad, Ebner Bon G Maceda, Angela Marie D Leyco, Sylvia C Estrada
Background and objective: Transient congenital hypothyroidism (TCH) refers to temporary deficiency of thyroid hormone identified after birth which later recovers to improved thyroxine production. Its prevalence in the Philippines has not been reported in a large-scale study. Its diagnosis remains difficult due to its numerous possible etiologies. Identifying the predictive factors of TCH may aid in earlier diagnosis and decreased risk of overtreatment. This study aimed to determine the predictive factors for TCH in children with congenital hypothyroidism (CH) detected by newborn screening (NBS) in the Philippines from January 2010 to December 2017.
Methods: In this multicenter retrospective cohort study involving 15 NBS continuity clinics in the Philippines, medical records were reviewed, and clinical and laboratory factors were compared between children with TCH and those with permanent congenital hypothyroidism (PCH). Of the 2,913 children diagnosed with CH in the Philippines from 2010 to 2017, 1,163 (39.92%) were excluded from the study due to an unrecalled or lost to follow-up status, or a concomitant diagnosis of Down Syndrome.
Results: Among the 1,750 patients included in analysis, 6.97% were diagnosed with TCH, 60.80% were female, mean gestational age at birth was 38 weeks, and mean birth weight was 2,841 grams. Confirmatory thyrotropin (TSH) was lower and confirmatory free thyroxine (FT4) was higher in the TCH group compared to those with PCH (TSH 32.80 vs 86.65 µIU/mL [p <0.0001]; FT4 9.90 vs 7.37 pmol/L [p 0.001]). The TCH group required lower L-thyroxine doses compared to the PCH group at treatment initiation and at 1, 2, and 3 years of age (initial 6.98 vs 12.08 µg/ kg/day [p <0.0001]; at 1 year 1.89 vs 4.11 µg/kg/day [p <0.0001]; at 2 years 1.21 vs 3.72 µg/kg/day [p <0.0001]; at 3 years 0.83 vs 3.45 µg/kg/day [p <0.0001]). Among those with TCH, mean serum TSH decreased significantly after treatment with L-thyroxine (32.80 vs. 6.55 µIU/ mL, p 0.0001). Other factors associated with TCH were results of thyroid ultrasonography (p 0.007), gestational age at birth (p 0.02), and maternal history of thyroid illness (p <0.0001).
Conclusion: Of all the patients with confirmed congenital hypothyroidism via the newborn screening, 6.97% were diagnosed with transient CH. Factors associated with TCH are confirmatory TSH and FT4, L-thyroxine dose requirements, thyroid ultrasound findings, gestational age at birth, and a maternal history of thyroid illness.
背景与目的:一过性先天性甲状腺功能减退症(TCH)是指出生后发现的甲状腺激素暂时缺乏,后来恢复到甲状腺素分泌改善。其在菲律宾的流行情况尚未在大规模研究中报告。由于其可能的病因众多,其诊断仍然很困难。确定TCH的预测因素可能有助于早期诊断和降低过度治疗的风险。本研究旨在确定2010年1月至2017年12月在菲律宾通过新生儿筛查(NBS)检测出的先天性甲状腺功能减退症(CH)儿童TCH的预测因素。方法:在这项涉及菲律宾15家NBS连续性诊所的多中心回顾性队列研究中,回顾了TCH儿童和永久性先天性甲状腺功能减退症(PCH)儿童的医疗记录,并比较了临床和实验室因素。在2010年至2017年菲律宾诊断为CH的2,913名儿童中,1,163名(39.92%)因未召回或丢失随访状态或伴随唐氏综合征诊断而被排除在研究之外。结果:纳入分析的1750例患者中,诊断为TCH的患者占6.97%,女性占60.80%,平均出生胎龄38周,平均出生体重2841 g。与PCH组相比,TCH组的确认性促甲状腺激素(TSH)较低,而确认性游离甲状腺素(FT4)较高(TSH 32.80 vs 86.65 μ IU/mL) [p]:通过新生儿筛查确诊的先天性甲状腺功能减退患者中,6.97%诊断为一过性甲状腺功能减退,与TCH相关的因素包括确认性TSH和FT4、l -甲状腺素剂量要求、甲状腺超声检查结果、出生时胎龄和母亲甲状腺疾病史。
{"title":"Predictive Factors of Transient Congenital Hypothyroidism among Filipino Children: A Retrospective Study.","authors":"Lorna R Abad, Ebner Bon G Maceda, Angela Marie D Leyco, Sylvia C Estrada","doi":"10.47895/amp.vi0.11965","DOIUrl":"10.47895/amp.vi0.11965","url":null,"abstract":"<p><strong>Background and objective: </strong>Transient congenital hypothyroidism (TCH) refers to temporary deficiency of thyroid hormone identified after birth which later recovers to improved thyroxine production. Its prevalence in the Philippines has not been reported in a large-scale study. Its diagnosis remains difficult due to its numerous possible etiologies. Identifying the predictive factors of TCH may aid in earlier diagnosis and decreased risk of overtreatment. This study aimed to determine the predictive factors for TCH in children with congenital hypothyroidism (CH) detected by newborn screening (NBS) in the Philippines from January 2010 to December 2017.</p><p><strong>Methods: </strong>In this multicenter retrospective cohort study involving 15 NBS continuity clinics in the Philippines, medical records were reviewed, and clinical and laboratory factors were compared between children with TCH and those with permanent congenital hypothyroidism (PCH). Of the 2,913 children diagnosed with CH in the Philippines from 2010 to 2017, 1,163 (39.92%) were excluded from the study due to an unrecalled or lost to follow-up status, or a concomitant diagnosis of Down Syndrome.</p><p><strong>Results: </strong>Among the 1,750 patients included in analysis, 6.97% were diagnosed with TCH, 60.80% were female, mean gestational age at birth was 38 weeks, and mean birth weight was 2,841 grams. Confirmatory thyrotropin (TSH) was lower and confirmatory free thyroxine (FT4) was higher in the TCH group compared to those with PCH (TSH 32.80 vs 86.65 µIU/mL [p <0.0001]; FT4 9.90 vs 7.37 pmol/L [p 0.001]). The TCH group required lower L-thyroxine doses compared to the PCH group at treatment initiation and at 1, 2, and 3 years of age (initial 6.98 vs 12.08 µg/ kg/day [p <0.0001]; at 1 year 1.89 vs 4.11 µg/kg/day [p <0.0001]; at 2 years 1.21 vs 3.72 µg/kg/day [p <0.0001]; at 3 years 0.83 vs 3.45 µg/kg/day [p <0.0001]). Among those with TCH, mean serum TSH decreased significantly after treatment with L-thyroxine (32.80 vs. 6.55 µIU/ mL, p 0.0001). Other factors associated with TCH were results of thyroid ultrasonography (p 0.007), gestational age at birth (p 0.02), and maternal history of thyroid illness (p <0.0001).</p><p><strong>Conclusion: </strong>Of all the patients with confirmed congenital hypothyroidism via the newborn screening, 6.97% were diagnosed with transient CH. Factors associated with TCH are confirmatory TSH and FT4, L-thyroxine dose requirements, thyroid ultrasound findings, gestational age at birth, and a maternal history of thyroid illness.</p>","PeriodicalId":6994,"journal":{"name":"Acta Medica Philippina","volume":"59 17","pages":"76-85"},"PeriodicalIF":0.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12697217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-31eCollection Date: 2025-01-01DOI: 10.47895/amp.vi0.8920
Siti Khotimah
<p><strong>Background: </strong>Hypercholesterolemia is one of the most important risk factors in causing coronary heart disease. Hypercholesterolemia occurs because cholesterol synthesis in the body increases. The key enzyme of the cholesterol synthesis is hydroxymethylglutaryl-CoA (HMG-CoA) reductase. Drugs that inhibit HMG-CoA reductase activity such as statins are effective in inhibiting cholesterol synthesis. The problem arises because these drugs have many side effects. The use of natural ingredients as traditional medicine has been practiced by communities for generations. This has led to massive exploration and scientific studies on the biological activities of these medicinal plants.</p><p><strong>Objective: </strong>Using an in-silico method, this study aimed to explore the pharmacokinetic and toxicity predictions, as well as the HMG-CoA reductase inhibitor activity of "Binahong" (<i>Anredera cordifolia</i> [Ten.] Steenis.) and elephant's foot (<i>Elephantopus scaber</i> Linn.).</p><p><strong>Methods: </strong>To collect samples, the Kanaya Knapsack database, USDA Dr Duke Phytochemical, PubChem, and Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) were used. To predict the activity of the active compounds, Pass Online software was used. To complete the drug-likeness analysis, the Lipinski rule of five and the Swiss Absorption, Distribution, Metabolism and Excretion (ADME) were employed. Protox II was used to predict the toxicity of the active compounds. Next, with PyRx v.0.9.8 software, molecular docking is utilized to do molecular screening. BioVia Discovery Studio 2019 was employed for data visualization.</p><p><strong>Results: </strong>A number of the bioactive compounds of <i>Anredera cordifolia</i> and <i>Elephantopus scaber</i> had pa values >0.3 which indicate predicted activity as antihypercholesterolemic. The results of the pharmacokinetic analysis showed similar properties to drugs, allowing them to be absorbed well in the intestines and have no penetration into the blood-brain barrier. Toxicity prediction of the bioactive compounds was in the non-toxic category, although caution is required. The molecular docking results showed that three active compounds from <i>Anredera cordifolia</i> namely Ursolic acid, Calenduloside E, and Larreagenin A had a more negative binding energy compared to atorvastatin. Likewise, the active compounds from the <i>Elephantopus scaber</i> that had more negative binding energy than atorvastatin are Epifriedelanol, Stigmasterol glucoside, and Lupeol. However, the bio-active compounds of Larreagenin A and Lupeol do not have amino acid residues similar to the control on the active site of binding to the HMG-CoA reductase.</p><p><strong>Conclusion: </strong>Both <i>Anredera cordifolia</i> and <i>Elephantopus scaber</i> plants showed potential as antihypercholesterolemic drugs through inhibition of HMG-CoA reductase activity, showed drug-likeness, and were able to be abs
背景:高胆固醇血症是引起冠心病最重要的危险因素之一。高胆固醇血症的发生是因为体内胆固醇合成增加。胆固醇合成的关键酶是羟甲基戊二酰辅酶a (HMG-CoA)还原酶。抑制HMG-CoA还原酶活性的药物,如他汀类药物,可有效抑制胆固醇合成。出现这个问题是因为这些药物有很多副作用。使用天然成分作为传统药物已经被社区实践了几代人。这导致了对这些药用植物生物活性的大量探索和科学研究。目的:本研究采用计算机模拟方法,探讨“宾那红”(Anredera cordifolia)的药动学、毒性预测及HMG-CoA还原酶抑制剂活性。)和象脚(Elephantopus scaber Linn.)方法:使用Kanaya backpack数据库、USDA Dr Duke Phytochemical、PubChem和结构生物信息学研究合作实验室蛋白质数据库(RCSB PDB)收集样本。利用Pass Online软件预测活性化合物的活性。采用利平斯基五法则和瑞士吸收、分布、代谢和排泄法(ADME)完成药物相似性分析。用Protox II预测活性化合物的毒性。接下来,利用PyRx v.0.9.8软件进行分子对接,进行分子筛选。BioVia Discovery Studio 2019用于数据可视化。结果:菖蒲和象皮的部分活性成分pa值为>0.3,表明其具有抗高胆固醇血症的活性。药代动力学分析的结果显示出与药物相似的特性,使它们在肠道中被很好地吸收,而不会渗透到血脑屏障中。生物活性化合物的毒性预测属于无毒类别,尽管需要谨慎。分子对接结果表明,与阿托伐他汀相比,熊果酸、金盏花苷E和Larreagenin A这3种活性物质具有更高的负结合能。同样地,从象皮中提取的比阿托伐他汀具有更多负结合能的活性化合物有:表丙烯醇、豆甾醇糖苷和鹿皮醇。然而,Larreagenin A和lupel的生物活性化合物在与HMG-CoA还原酶结合的活性位点上没有与对照相似的氨基酸残基。结论:菖菖树和象皮植物均可通过抑制HMG-CoA还原酶活性,具有抗高胆固醇药物的潜力,具有药物相似性,且在肠内吸收良好,不穿透血脑屏障。这两种植物的治疗效果还需要进一步的体内和体外研究。
{"title":"In-Silico Screening of HMG-CoA Reductase Inhibition Potential from <i>Anredera cordifolia</i> (Ten.) Steenis and <i>Elephantopus scaber</i> Linn.","authors":"Siti Khotimah","doi":"10.47895/amp.vi0.8920","DOIUrl":"10.47895/amp.vi0.8920","url":null,"abstract":"<p><strong>Background: </strong>Hypercholesterolemia is one of the most important risk factors in causing coronary heart disease. Hypercholesterolemia occurs because cholesterol synthesis in the body increases. The key enzyme of the cholesterol synthesis is hydroxymethylglutaryl-CoA (HMG-CoA) reductase. Drugs that inhibit HMG-CoA reductase activity such as statins are effective in inhibiting cholesterol synthesis. The problem arises because these drugs have many side effects. The use of natural ingredients as traditional medicine has been practiced by communities for generations. This has led to massive exploration and scientific studies on the biological activities of these medicinal plants.</p><p><strong>Objective: </strong>Using an in-silico method, this study aimed to explore the pharmacokinetic and toxicity predictions, as well as the HMG-CoA reductase inhibitor activity of \"Binahong\" (<i>Anredera cordifolia</i> [Ten.] Steenis.) and elephant's foot (<i>Elephantopus scaber</i> Linn.).</p><p><strong>Methods: </strong>To collect samples, the Kanaya Knapsack database, USDA Dr Duke Phytochemical, PubChem, and Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) were used. To predict the activity of the active compounds, Pass Online software was used. To complete the drug-likeness analysis, the Lipinski rule of five and the Swiss Absorption, Distribution, Metabolism and Excretion (ADME) were employed. Protox II was used to predict the toxicity of the active compounds. Next, with PyRx v.0.9.8 software, molecular docking is utilized to do molecular screening. BioVia Discovery Studio 2019 was employed for data visualization.</p><p><strong>Results: </strong>A number of the bioactive compounds of <i>Anredera cordifolia</i> and <i>Elephantopus scaber</i> had pa values >0.3 which indicate predicted activity as antihypercholesterolemic. The results of the pharmacokinetic analysis showed similar properties to drugs, allowing them to be absorbed well in the intestines and have no penetration into the blood-brain barrier. Toxicity prediction of the bioactive compounds was in the non-toxic category, although caution is required. The molecular docking results showed that three active compounds from <i>Anredera cordifolia</i> namely Ursolic acid, Calenduloside E, and Larreagenin A had a more negative binding energy compared to atorvastatin. Likewise, the active compounds from the <i>Elephantopus scaber</i> that had more negative binding energy than atorvastatin are Epifriedelanol, Stigmasterol glucoside, and Lupeol. However, the bio-active compounds of Larreagenin A and Lupeol do not have amino acid residues similar to the control on the active site of binding to the HMG-CoA reductase.</p><p><strong>Conclusion: </strong>Both <i>Anredera cordifolia</i> and <i>Elephantopus scaber</i> plants showed potential as antihypercholesterolemic drugs through inhibition of HMG-CoA reductase activity, showed drug-likeness, and were able to be abs","PeriodicalId":6994,"journal":{"name":"Acta Medica Philippina","volume":"59 16","pages":"100-108"},"PeriodicalIF":0.0,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12666097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145659823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}